EA201791167A1 - Способы и композиции для мечения радиоактивным изотопомf биологических препаратов - Google Patents

Способы и композиции для мечения радиоактивным изотопомf биологических препаратов

Info

Publication number
EA201791167A1
EA201791167A1 EA201791167A EA201791167A EA201791167A1 EA 201791167 A1 EA201791167 A1 EA 201791167A1 EA 201791167 A EA201791167 A EA 201791167A EA 201791167 A EA201791167 A EA 201791167A EA 201791167 A1 EA201791167 A1 EA 201791167A1
Authority
EA
Eurasian Patent Office
Prior art keywords
isotopom
radioactive
compositions
switching
methods
Prior art date
Application number
EA201791167A
Other languages
English (en)
Other versions
EA034516B1 (ru
Inventor
Дэвид Доннелли
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201791167A1 publication Critical patent/EA201791167A1/ru
Publication of EA034516B1 publication Critical patent/EA034516B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
    • G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
    • G01T1/29—Measurement performed on radiation beams, e.g. position or section of the beam; Measurement of spatial distribution of radiation
    • G01T1/2914—Measurement of spatial distribution of radiation
    • G01T1/2985—In depth localisation, e.g. using positron emitters; Tomographic imaging (longitudinal and transverse section imaging; apparatus for radiation diagnosis sequentially in different planes, steroscopic radiation diagnosis)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к водорастворимымF-простетическим группам и раскрывает синтез и применениеF-меченых биологических молекул, содержащихF-простетические группы, для визуализации различных процессов, протекающих в организме, детекции локализации молекул, ассоциированных с патологией заболевания, и мониторинга прогрессирования заболевания.
EA201791167A 2014-11-25 2015-11-24 Способы и композиции для мечения радиоактивным изотопомf биологических препаратов EA034516B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462084366P 2014-11-25 2014-11-25
PCT/US2015/062502 WO2016086036A2 (en) 2014-11-25 2015-11-24 Methods and compositions for 18f-radiolabeling of biologics

Publications (2)

Publication Number Publication Date
EA201791167A1 true EA201791167A1 (ru) 2017-11-30
EA034516B1 EA034516B1 (ru) 2020-02-14

Family

ID=54834953

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791167A EA034516B1 (ru) 2014-11-25 2015-11-24 Способы и композиции для мечения радиоактивным изотопомf биологических препаратов

Country Status (10)

Country Link
US (2) US11229713B2 (ru)
EP (2) EP4218832A3 (ru)
JP (2) JP6701217B2 (ru)
CN (1) CN107207379B (ru)
BR (1) BR112017010414A2 (ru)
CA (1) CA2968961A1 (ru)
EA (1) EA034516B1 (ru)
ES (1) ES2941895T3 (ru)
MX (1) MX2017006785A (ru)
WO (1) WO2016086036A2 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067337A1 (en) * 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
ES2822990T3 (es) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EA038019B1 (ru) 2016-05-19 2021-06-23 Бристол-Маерс Сквибб Компани Иммуномодуляторы для пэт-визуализации
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
WO2018111978A1 (en) * 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
US10626165B2 (en) * 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
JP7206222B2 (ja) 2017-06-23 2023-01-17 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－１のアンタゴニストとして作用する免疫調節剤
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CA3092421A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
US11766243B2 (en) * 2018-03-13 2023-09-26 Trust Bio-Sonics, Inc. Composition and methods for sensitive molecular analysis
CN108680637A (zh) * 2018-05-15 2018-10-19 苏州大学 基于马来酰亚胺衍生物组合的非同位素双标记方法
CN109239758B (zh) * 2018-07-27 2022-08-12 国家海洋局南海环境监测中心（中国海监南海区检验鉴定中心） 一种生物样品中伽马能谱核素检测分析方法
CN109350751B (zh) * 2018-09-05 2021-08-31 南方医科大学南方医院 一种靶向egfr的多肽类pet显像剂及其制备方法和应用
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
CN111856546B (zh) * 2020-06-23 2022-07-29 中国辐射防护研究院 一种关于海洋生物灰中Cs-137放化分析的制样方法
GB202108605D0 (en) * 2021-06-16 2021-07-28 Ge Healthcare Uk Ltd Effect of water content
WO2023014999A1 (en) * 2021-08-06 2023-02-09 The Johns Hopkins University Aluminum fluoride radiosynthesis of [18f]dk222

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
WO1997041898A1 (en) 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
AU725827B2 (en) 1996-07-12 2000-10-19 Immunomedics Inc. Radiometal-binding peptide analogues
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
WO1999011590A1 (en) 1997-09-03 1999-03-11 Immunomedics, Inc. Fluorination of proteins and peptides for f-18 positron emission tomography
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
ES2564161T3 (es) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
US7556925B2 (en) 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
CA2564076C (en) 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
CA2627046C (en) 2005-10-26 2015-09-15 Medarex, Inc. Methods and compounds for preparing cc-1065 analogs
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
WO2008073458A2 (en) 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
TW200900059A (en) 2007-02-21 2009-01-01 Medarex Inc Chemical linkers with single amino acids and conjugates thereof
AU2008287426B2 (en) 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
EP2036576A1 (en) 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
CA2704229C (en) 2007-10-31 2019-05-07 Medimmune, Llc Protein scaffolds comprising seven beta strand domains and six loop regions
JP2011507529A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｍ１３ファージのｐＩＸへの融合を介する代替の足場タンパク質融合ファージ提示
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
US20100322930A1 (en) 2007-12-27 2010-12-23 Frank Kolbinger Fibronectin-based binding molecules and their use
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
WO2009133208A1 (en) 2008-05-02 2009-11-05 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US9217210B2 (en) 2009-03-24 2015-12-22 North Carolina State University Process of making composite inorganic/polymer nanofibers
EP2464663A4 (en) 2009-08-13 2013-05-29 Massachusetts Inst Technology RECOMBINANT PROTEINS COMPRISING MUTANT DOMAINS OF FIBRONECTIN
ES2860453T3 (es) 2009-10-30 2021-10-05 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP3569256B1 (en) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP3248987A1 (en) 2010-07-30 2017-11-29 Novartis AG Fibronectin cradle molecules and libraries thereof
PT2697257T (pt) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Proteínas de fusão fc compreendendo novos ligantes ou arranjos
WO2013010573A1 (en) 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
CN104768969B (zh) 2012-09-13 2021-04-16 百时美施贵宝公司 结合至肌生成抑制素的基于纤连蛋白的支架结构域蛋白
ES2755804T3 (es) 2012-12-03 2020-04-23 Curasight Aps Péptidos marcados con un radionúclido que emite positrones para obtención de imágenes de PET del uPAR humana
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (en) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
CN105377287A (zh) 2013-02-15 2016-03-02 托马斯杰弗逊大学 用于肿瘤成像的试剂盒
US9433689B2 (en) 2013-03-12 2016-09-06 The Board Of Trustees Of The Leland Stanford Junio Probes and methods of imaging non-Hodgkins lymphoma
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
EP3647322B1 (en) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
MX2016011580A (es) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Dominios de fibronectina tipo iii que se unen a albumina de suero.
WO2015190613A1 (en) 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Radiolabeled compounds
CA2994927A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University High affinity pd-1 agents and methods of use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
ES2822990T3 (es) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
WO2016162368A1 (en) 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-invasive imaging of tumor pd-l1 expression
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
JP6990652B2 (ja) 2015-10-30 2022-02-03 アフィボディ・アーベー 新規ポリペプチド
CN108290931A (zh) 2015-10-30 2018-07-17 阿菲博迪公司 对pd-l1具有亲和力的新的多肽
ES2856968T3 (es) 2016-01-15 2021-09-28 Rigshospitalet Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
CN109562195A (zh) 2016-06-01 2019-04-02 百时美施贵宝公司 用pd-l1结合多肽进行pet成像

Also Published As

Publication number Publication date
JP2018503679A (ja) 2018-02-08
WO2016086036A3 (en) 2016-07-07
US11229713B2 (en) 2022-01-25
US20220184239A1 (en) 2022-06-16
EP3223866A2 (en) 2017-10-04
EP4218832A2 (en) 2023-08-02
WO2016086036A2 (en) 2016-06-02
MX2017006785A (es) 2017-09-05
US20180326098A1 (en) 2018-11-15
CN107207379B (zh) 2021-08-10
JP7027480B2 (ja) 2022-03-01
CA2968961A1 (en) 2016-06-02
EA034516B1 (ru) 2020-02-14
EP3223866B1 (en) 2023-03-08
BR112017010414A2 (pt) 2018-05-15
ES2941895T3 (es) 2023-05-26
EP4218832A3 (en) 2023-08-23
JP2020122007A (ja) 2020-08-13
CN107207379A (zh) 2017-09-26
JP6701217B2 (ja) 2020-05-27

Similar Documents

Publication Publication Date Title
EA201791167A1 (ru) Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201892635A1 (ru) Иммуномодуляторы для пэт-визуализации
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201691541A1 (ru) Новые анти-baff антитела
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
PH12018500701A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201691702A1 (ru) Химерные белки мти
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
WO2016090163A3 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
TR201906876T4 (tr) Amniyotik sıvının tanımlanması için tanısal kompozisyon.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM